INmune Bio Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient\'s innate immune system to treat cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood; and XPro1595 for the treatment of Alzheimer\'s disease. The company was founded in 2015 and is based in La Jolla, California. The company trades on NASDAQ exchange. The company headquarter is located in La Jolla, CA. The company was established in the 2015.

TickerINMB
Long NameInmune Bio, Inc.
Short NameInmune Bio